Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.18), $0.06 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• PG&E Corp, Edison spike on chatter
• Action Behavior Centers' Family Advocacy Team Meets with Congressional Leaders in Washington, D.C., to Discuss Access to ABA Therapy for Autism
• Apple new CEO Ternus teases "phenomenal" iPhone launch in first memo